Market closed · data as of 27 Aug 2026 · source NSE via Alphave. Open the live chart →
Eris Lifesciences is an Ahmedabad-based pure-play domestic branded formulations company focused on chronic and sub-chronic therapies — diabetes care, cardiology, CNS and dermatology (via the Oaknet acquisition) — sold through prescription-driven marketing to specialists. It has expanded into insulins and biologics (acquiring Biocon Biologics' domestic branded formulations business) and sterile injectables (Swiss Parenterals), adding manufacturing depth and export optionality to a historically India-only model. Revenue is driven by chronic-therapy prescription growth and integration of acquired portfolios.
It is among the fastest-growing Indian pharma companies in chronic domestic therapies, with industry-leading margins in its cohort.
Eris Lifesciences Ltd. is a constituent of NIFTY 500, NIFTY SMALLCAP 250. See where it sits on the market heatmap →
Consolidated annual figures taken from Eris Lifesciences Ltd.'s own filed statements — not estimates, and not restated by us. The most recent period shown is FY26 (year ended 31 Mar 2026).
| Metric | FY26 | FY25 | FY24 |
|---|---|---|---|
| EPS (basic, ₹) | 45.33 | 25.85 | 28.82 |
| Book value / share (₹) | 281.28 | 240.22 | 236.86 |
| Return on equity | 15.9% | 10.8% | 12.2% |
| Return on capital employed | 15.9% | 12.4% | 10.9% |
| Operating margin | 26.9% | 24.3% | 24.5% |
| Net margin | 20.7% | 12.9% | 19.8% |
| EBITDA | ₹1,120 Cr | ₹1,017 Cr | ₹675 Cr |
| Free cash flow | ₹241 Cr | ₹910 Cr | ₹357 Cr |
| Total debt | ₹2,310 Cr | ₹2,478 Cr | ₹2,735 Cr |
| Debt to equity | 0.59 | 0.76 | 0.85 |
| Interest coverage | 4.4 | 3.0 | 5.8 |
| Current ratio | 0.74 | 0.91 | 0.91 |
| Shares outstanding | 13,85,00,000 | 13,62,00,000 | 13,60,30,000 |
Open the full income statement, balance sheet and cash flow for ERIS →
As disclosed for the quarter ended 30 Jun 2026.
Institutional ownership changes quarter to quarter. See daily FII and DII flows across the market →
Companies Alphave classifies in the same sub-sector, closest by market capitalisation.